Antimicrobial stewardship

Arkstone Expands the Fight Against Antimicrobial Resistance to New Fronts with the Launch of GlobalGuidance

Retrieved on: 
Wednesday, February 28, 2024

BOCA RATON, Fla., Feb. 28, 2024 /PRNewswire/ -- Arkstone Medical Solutions, the leading force in laboratory infectious disease reporting and proactive antimicrobial stewardship, is proud to announce the global expansion of its fight against antimicrobial resistance with the launch of GlobalGuidance™.

Key Points: 
  • BOCA RATON, Fla., Feb. 28, 2024 /PRNewswire/ -- Arkstone Medical Solutions, the leading force in laboratory infectious disease reporting and proactive antimicrobial stewardship, is proud to announce the global expansion of its fight against antimicrobial resistance with the launch of GlobalGuidance™.
  • Arkstone recognizes the critical need for a global approach to antimicrobial stewardship, considering the diverse healthcare landscapes and linguistic variations across different regions.
  • Dr. Ari Frenkel, Chief Science Officer at Arkstone, expressed his enthusiasm for the global impact of GlobalGuidance, stating, "The launch of GlobalGuidance signifies a pivotal moment in our commitment to combating antimicrobial resistance on a global scale.
  • As Arkstone continues to pioneer advancements in infectious disease analysis and antimicrobial stewardship, the launch of GlobalGuidance marks a significant step towards achieving a global impact in the fight against antimicrobial resistance.

Inovalon's VigiLanz Solution Ranked No. 1 by KLAS Research in Pharmacy Surveillance and Infection Control and Monitoring

Retrieved on: 
Wednesday, February 21, 2024

1 in Pharmacy Surveillance, solidifying its position as the market leader in pharmacy surveillance software and bringing the company's total count of KLAS awards to 14.

Key Points: 
  • 1 in Pharmacy Surveillance, solidifying its position as the market leader in pharmacy surveillance software and bringing the company's total count of KLAS awards to 14.
  • "We are honored to be recognized as Best in KLAS for Pharmacy Surveillance for the seventh year in a row, and to be named the industry leader in Infection Control and Monitoring," said Dr. Hayley Burgess, SVP, Provider Surveillance and Safety at Inovalon.
  • VigiLanz Pharmacy Surveillance continuously monitors data from the EHR and ancillary clinical systems to improve medication safety, standardize practices, and maximize efficiencies.
  • Selected commentary collected about VigiLanz Infection Control and Monitoring and Pharmacy Surveillance, January 2024 © 2024 KLAS.

Arkstone Launches Innovative Clinical Study to Evaluate OneChoice Report's Impact on Antimicrobial Prescribing, Stewardship, and Patient Outcomes

Retrieved on: 
Tuesday, January 9, 2024

This joint effort marks a significant advancement in the appropriate antimicrobial prescribing and the fight against antibiotic resistance.

Key Points: 
  • This joint effort marks a significant advancement in the appropriate antimicrobial prescribing and the fight against antibiotic resistance.
  • The study aims to evaluate the clinical utility and benefits of Arkstone's innovative clinical decision support software, the OneChoice Report®, and its impact on selecting appropriate antibiotic therapy.
  • "The OneChoice Report is the most advanced antimicrobial stewardship program available, providing guidance to clinicians on optimal therapy for infections.
  • The study will also investigate the relationship between the use of the OneChoice Report®, clinician usage, antibiotic selection, patient outcomes, and healthcare cost-effectiveness.

Krishi unveils transformative in-clinic diagnostic platform

Retrieved on: 
Monday, January 8, 2024

WEST LAFAYETTE, Ind., Jan. 8, 2024 /PRNewswire/ -- SHERPA™ sure-footed antibiotic guidance puts patient treatment on the right path from day one. This easy-to-use, in-clinic molecular diagnostic platform delivers accurate, lab-quality antibiotic guidance to veterinarians in one hour or less. With SHERPA™, veterinarians can avoid best-guess antibiotic selection, speeding patient recovery with less discomfort, while enhancing antimicrobial stewardship.

Key Points: 
  • For bacterial urinary tract or skin infections in dogs and cats, easy-to-use, loT connected SHERPA™ enables targeted antibiotic treatment within one hour.
  • WEST LAFAYETTE, Ind., Jan. 8, 2024 /PRNewswire/ -- SHERPA™ sure-footed antibiotic guidance puts patient treatment on the right path from day one.
  • This easy-to-use, in-clinic molecular diagnostic platform delivers accurate, lab-quality antibiotic guidance to veterinarians in one hour or less.
  • With SHERPA™, veterinarians can avoid best-guess antibiotic selection, speeding patient recovery with less discomfort, while enhancing antimicrobial stewardship.

ALK to Become Sole Manufacturer and Distributor of Skin Antigen Test for Penicillin Allergy

Retrieved on: 
Thursday, January 4, 2024

BEDMINSTER, N.J., Jan. 4, 2024 /PRNewswire/ -- The Danish, pharmaceutical company ALK (ALKB:DC / OMX: ALK B / AKBLF), today announced it has successfully completed its acquisition of the business assets of AllerQuest, a U.S.-based company dedicated to manufacturing PRE-PEN® (benzylpenicilloyl polylysine injection USP) Skin Antigen Test. This acquisition makes ALK the sole manufacturer and distributor of PRE-PEN in the U.S. and Canada, with global ownership rights to all assets of AllerQuest.

Key Points: 
  • This acquisition makes ALK the sole manufacturer and distributor of PRE-PEN in the U.S. and Canada, with global ownership rights to all assets of AllerQuest.
  • James Wolfe, M.D., President of AllerQuest says: "We are proud of our partnership with ALK for over 14 years to distribute PRE-PEN in the U.S. and Canada.
  • ALK is well-positioned to assume manufacturing capabilities for PRE-PEN and will continue to provide this important test to the millions of patients who are labelled as penicillin allergic."
  • ALK expects the acquisition to strengthen its American business, but it will not have a material financial impact on the company's financial results for 2024.

Artificial Intelligence-Powered Drug Diversion Surveillance Now Part of Wolters Kluwer’s Sentri7 Suite

Retrieved on: 
Thursday, November 30, 2023

To better equip healthcare facilities to address this growing threat to patient and staff safety, Wolters Kluwer Health is expanding its Sentri7® clinical surveillance suite to include the Sentri7 Drug Diversion solution, formerly Flowlytics® from Invistics.1

Key Points: 
  • To better equip healthcare facilities to address this growing threat to patient and staff safety, Wolters Kluwer Health is expanding its Sentri7® clinical surveillance suite to include the Sentri7 Drug Diversion solution, formerly Flowlytics® from Invistics.1
    Despite an increasing number of solutions available on the market to address drug diversion, healthcare executives’ confidence remains low.
  • The 2023 State of Drug Diversion Survey found only 40% of executives are very confident in the efficacy of their drug diversion detection programs.
  • Powered by AI and machine learning, the Sentri7 Drug Diversion solution aims to address these gaps in confidence with a proven track record of proactive drug diversion surveillance that minimizes the burden on hospital staff.
  • “Using the Sentri7 Drug Diversion solution, my team is in a better position to be proactive in our drug diversion surveillance, ultimately supporting heightened safety across our organization.

KONZA National Network and Kansas Department of Health and Environment Pioneer Public Health Project

Retrieved on: 
Wednesday, November 29, 2023

TOPEKA, Kan., Nov. 29, 2023 /PRNewswire/ -- KONZA National Network has partnered with the Kansas Department of Health and Environment (KDHE) to pioneer a nationwide first: a pilot project that provides real-time alerting to prevent the spread of multidrug-resistant organisms (MDROs).

Key Points: 
  • TOPEKA, Kan., Nov. 29, 2023 /PRNewswire/ -- KONZA National Network has partnered with the Kansas Department of Health and Environment (KDHE) to pioneer a nationwide first: a pilot project that provides real-time alerting to prevent the spread of multidrug-resistant organisms (MDROs).
  • While KDHE's MDRO project is the inception and base for RapidAlerts Direct, the product is scalable across other Public Health Departments and across other alert types.
  • "The application of RapidAlerts Direct is wide-ranging beyond its current use for MDRO alerts and has significant opportunity to improve public health on a national level," said Chris Guerrero, Director of Public Health Services for KONZA.
  • "Our partnership with KDHE on this vital project underscores our shared commitment to advancing public health outcomes."

Veterinary Chemistry Analyzers Market Size Projected to Touch USD 8.26 Billion By 2032, Increasing at 12.7% CAGR Globally: Polaris Market Research

Retrieved on: 
Monday, October 23, 2023

"According to research report, the global veterinary chemistry analyzer market size/share was valued at USD 2.50 Billion in 202 and is expected to touch USD 8.26 Billion by 2032, growing at a CAGR of 12.7% during the forecast period."

Key Points: 
  • "According to research report, the global veterinary chemistry analyzer market size/share was valued at USD 2.50 Billion in 202 and is expected to touch USD 8.26 Billion by 2032, growing at a CAGR of 12.7% during the forecast period."
  • Global Veterinary Chemistry Analyzers Market: Report Overview
    A veterinary chemistry analyzer is a medical device utilized in veterinary clinics and laboratories to scrutinize several variables in animal blood, urine, and other bodily fluids.
  • These diagnostic instruments are engaged for assay and biochemical testing in veterinary medicines for experimenting with animal diseases.
  • The veterinary chemistry analyzer market segmentation is primarily based on type, product, species, application, end-use, and region.

Latest Clinical Evidence Presented at APWCA's Wound Week™ 2023 Illustrates the Significant and New Clinical Utility of the MolecuLight Point-of-Care Imaging Platform

Retrieved on: 
Thursday, September 21, 2023

Wound Week is a leading multidisciplinary meeting of wound care professionals that presents cutting-edge clinical findings and best practices presented by its expert faculty.

Key Points: 
  • Wound Week is a leading multidisciplinary meeting of wound care professionals that presents cutting-edge clinical findings and best practices presented by its expert faculty.
  • "The evidence is irrefutable," says Dr. Thomas Serena, the Founder and Medical Director of The SerenaGroup®.
  • "We are thrilled with the significant additional clinical evidence being presented at Wound Week 2023 showing the impressive results derived from MolecuLight point-of-care devices," says Anil Amlani, MolecuLight's CEO.
  • "The clinical insights that are informed by the MolecuLight platform span the wound care continuum, including wound hygiene, wound bed preparation, antimicrobial stewardship, and patient engagement (through the incorporation of MolecuLight).

Resistance to antibiotics in northern Nigeria: what bacteria are prevalent, and which drugs work against them

Retrieved on: 
Sunday, September 17, 2023

Antimicrobial resistance – the ability of microorganisms to resist drugs that have been developed to control them – is a severe problem in African countries.

Key Points: 
  • Antimicrobial resistance – the ability of microorganisms to resist drugs that have been developed to control them – is a severe problem in African countries.
  • The continent has the highest global burden of antimicrobial-resistant infections, with 114.8 deaths per 100,000 people.
  • Physicians need laboratory data to choose the right antibiotic, at the right dose, for the right period of time.
  • This can lead to choosing ineffective antibiotics, which can lead to increases in resistant bacteria.
  • In other words, to develop a list of what bacteria are prevalent in the region and which drugs work against them.
  • To accomplish this, we recently conducted a study of multidrug-resistant bacteria obtained from patients in six hospitals in northern Nigeria.

Drug-resistant bacteria in Nigeria

    • We chose to analyse bacteria that are resistant to more than one drug because they are the biggest challenge when treating infections.
    • We found that about 85% of the bacteria isolated from infections were resistant to the most commonly used antibiotics.
    • The good news was that two antibiotics, tigecycline and fosfomycin, remained very active even against highly resistant strains of bacteria.

Genetic mechanisms

    • This was done to understand what made these organisms so resistant to antibiotics at the molecular level.
    • The data revealed an astonishingly high number of genetic mechanisms making the microorganisms resistant.
    • In some cases, the genetic information encoding resistance was capable of being shared among other microorganisms.

The need for antimicrobial stewardship

    • Some of the resistance genes were capable of moving from one microorganism to another (mobile resistance genes).
    • Antimicrobial stewardship based on laboratory data is effective especially if done locally, regionally and nationally.

Antimicrobial resistance is everyone’s concern

    • Read more:
      Antimicrobial resistance calls for brainpower of a space agency and campaigning zeal of an NGO

      Fourth, there are things that everyone can do to help bring antibiotic resistance under control.

    • For example, the US Centers for Disease Control and Prevention list five things that everyone should know about drug resistance and 10 activities to protect yourself and your family against resistance.
    • He is affiliated with the International Society for Antimicrobial Chemotherapy.